Sjogren Syndrome after Radioiodine Therapy in Thyroid Cancer Patients
이희진, 김재정, 김영건, 안형준, 최종훈, 권정승,
소속 상세정보
이희진 ( Lee Hee-Jin ) - Yonsei University College of Dentistry Department of Orofacial Pain and Oral Medicine
김재정 ( Kim Jae-Jeong ) - Yonsei University College of Dentistry Department of Orofacial Pain and Oral Medicine
김영건 ( Kim Young-Gun ) - Yonsei University College of Dentistry Department of Orofacial Pain and Oral Medicine
안형준 ( Ahn Hyung-Joon ) - Yonsei University College of Dentistry Department of Orofacial Pain and Oral Medicine
최종훈 ( Choi Jong-Hoon ) - Yonsei University College of Dentistry Department of Orofacial Pain and Oral Medicine
권정승 ( Kwon Jeong-Seung ) - Yonsei University College of Dentistry Department of Orofacial Pain and Oral Medicine
Abstract
Salivary and lacrimal gland dysfunction is relatively frequent after radioiodine therapy. In most cases this is a transient side effect, but in some patients it may persist for a long period or appear late. Radioiodine (131I) therapy is often administered to patients following total thyroidectomy to treat well-differentiated follicular cell-derived thyroid cancer. In addition to thethyroid, 131I accumulates in the salivary glands, giving rise to transient or permanent salivary gland damage. Salivary gland dysfunction following radioiodine therapy can be caused by radiation damage. But, it also may be associated with Sjogren syndrome (SS) developed after radioiodine therapy. It would be recommended that the evaluation for SS including anti-SSA/Ro and anti-SSB/La should be considered before and after radioiodine therapy.
키워드
Sjogren’s syndrome; Thyroid neoplasms; Xerostomia
원문 및 링크아웃 정보
등재저널 정보